Delivery Order SPE2DB20D3103-SPE2DB25FN5S3
Award Date 4/24/25
Potential Completion Date 4/25/25
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $30,729.94 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions, indicating this procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,651.82 to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes on November 25, 2025, with an ultimate completion date of November 26, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. ENBREL is a biologic pharmaceutical commonly used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Enbrel 25 mg/0.5 mL syringes with a ceiling value of $12,585.95. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by November 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Enbrel is a biologic immunosuppressant used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $14,477.73 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL syringes on December 19, 2025, with completion scheduled for December 22, 2025. ENBREL is a biologic medication used to treat rheumatoid arthritis and other autoimmune conditions. This delivery order was awarded under firm fixed-price terms with no set-aside designation, reflecting competitive procurement practices. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $41,484.36 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This firm fixed-price, competitively awarded contract (no set-aside used) is scheduled for completion by November 6, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Enbrel is a critical biologic medication used primarily for treating rheumatoid arthritis and other autoimmune conditions,...
- The Defense Logistics Agency awarded a $6,032.22 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of June 20, 2025. This non-set-aside competitive award was issued on June 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, making this a specialized...
- The Defense Logistics Agency awarded a delivery order valued at $4,863.18 to AmerisourceBergen Drug Corp for the supply of ENBREL 25 mg/0.5 mL syringes on November 17, 2025, with an ultimate completion date of November 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. ENBREL is a TNF inhibitor used to treat rheumatoid arthritis, psoriasis, and other...
- The Defense Logistics Agency awarded a $21,586.91 delivery order to AmerisourceBergen Drug Corp on January 14, 2026, for the supply of Enbrel 50 mg/mL syringes. This firm fixed-price, non-competitive delivery order is scheduled for completion by January 15, 2026, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Enbrel is a biologic immunosuppressant used primarily in the treatment of rheumatoid arthritis and other autoimmune conditions, representing...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $42,400.52 for Enbrel 50 mg/ml syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child award issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $15,447.06 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This non-competitive, firm fixed-price delivery order was issued on November 3, 2025, with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Enbrel is a biologic medication used to treat autoimmune conditions including rheumatoid arthritis, and this...